FOLH1 and neoplasm: Figure 2 and Figure 3 show typical clinical cases of complete response (disappearance of all lesions or adenopathies less than 10 mm short axis) and partial response (decrease of at least 30% in the sum of the largest diameters of lesions compared with the baseline study) after 177Lu-iPSMA therapy. In addition, the reduction of large tumors and multiple metastatic lesions are proof of the high specificity and molecular recognition of 177Lu iPSMA by PSMA at the tumor cell level (Appendix A) (Figure A1, Figure A2 and Figure A3).